ReviewMetabolic brain disease2026
Animal models of multiple sclerosis: applications and future directions in disease research.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disorder of the central nervous system that affects nearly two million individuals worldwide. Characterized by axonal damage, neurodegeneration, and immune-mediated demyelination, MS remains without a cure, and its precise etiology is still unclear. Evidence strongly supports the role of autoimmune mechanisms, with both environmental factors and genetic contributing to disease onset and progression. Animal models have been indispensable in advancing our understanding of MS pathogenesis and in testing therapeutic strategies. Among these, experimental autoimmune encephalomyelitis is the most widely used, closely reproducing immune-mediated inflammation and demyelination. Viral models, such as Theiler's murine encephalomyelitis virus and Semliki Forest virus, provide insights into virus-induced demyelination, while toxin-induced models (e.g., cuprizone and lysolecithin) are valuable for studying demyelination and remyelination processes. Additionally, transgenic and knockout models allow the exploration of specific genetic contributions to disease mechanisms. Despite their limitations no single model fully recapitulates the heterogeneity of MS these approaches remain critical for unraveling disease mechanisms, identifying biomarkers, and developing novel therapeutic interventions. This review highlights the applications and limitations of existing animal models and discusses emerging directions in MS research.
Indexed as
Identifiers
41902989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.